
MM120 Shows Rapid and Lasting Anxiety Reduction in Phase 3 Generalized Anxiety Disorder Trials
Early phase 3 results show that a single dose of MM120 can rapidly reduce anxiety symptoms in GAD patients, with effects lasting up to 12 weeks.
MindMed’s Chief Medical Officer, Daniel Karlin, MD, MA, has announced the launch of
MM120 presents 3 major advantages over existing GAD treatments, which primarily include selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines. First, MM120 acts rapidly, with anxiety reductions observed within a day, compared to the weeks required for SSRIs. Second, a single dose has shown to produce long-lasting effects up to 12 weeks, with phase 3 trials extending follow-up to a full year. Third, the magnitude of improvement is significantly greater than that seen with traditional treatments, showing an effect size of 0.7 to 0.8 compared to 0.3 for SSRIs.
Phase 2 trials confirmed that 100 micrograms is the optimal dose, demonstrating strong efficacy, durability, and an acceptable safety profile. While MM120 does produce acute perceptual and emotional changes on the day of treatment, it does not carry the prolonged side effect burden associated with daily medications.
MindMed is currently recruiting participants for both Voyage and Panorama. With these groundbreaking trials, MM120 is positioning itself as a potential game-changer in GAD treatment.Bottom of Form
Dr Karlin is the chief medical officer of MindMed and a fellow of the APA.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.